Canonica GW, et al. - Researchers conducted this observational, multicenter PROXIMA study to determine the prevalence of perennial vs seasonal allergic asthma (cross-sectional phase, n=357) and the effect of omalizumab on improving illness perception, quality of life (QoL), and asthma control of Italian patients with severe allergic asthma (longitudinal phase, n=123). During the longitudinal phase, patients were administered omalizumab (75–600 mg subcutaneously every month) and were followed-up for 12 months. According to results, omalizumab administration led to improvement in patient-reported outcomes such as patients’ illness perception and QoL in severe allergic asthma, while verifying improvement of asthma control and exacerbation rate reduction in Italian patients.